Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma

• Published in: Leukemia & lymphoma Vol. 45; no. 9; pp. 1815 - 1819
• Main Authors: Zinzani, Pier Luigi, Pulsoni, Alessandro, Gentilini, Patrizia, Visani, Giuseppe, Perrotti, Alessio, Molinari, Anna Lia, Guardigni, Luciano, Tani, Monica, Villivà, Nicoletta, Stefoni, Vittorio, Alinari, Lapo, Martelli, Maurizio, Bonifazi, Francesca, Pileri, Stefano, Tura, Sante, Baccarani, Michele
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 01.09.2004; Taylor & Francis
• Subjects: Adult; Aged; Aging - physiology; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Drug Therapy, Combination; Female; First-line therapy; Fludarabine; Humans; Idarubicin - adverse effects; Idarubicin - therapeutic use; idarubicin and cyclophosphamide; Lymphoma, Non-Hodgkin - drug therapy; Male; Middle Aged; Non-follicular LG-NHL; Treatment Outcome; Vidarabine - adverse effects; Vidarabine - analogs & derivatives; Vidarabine - therapeutic use

In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to be effective in the treatment of previously untreated low-grade non-Hodgkin's lymphomas (LG-NHL). We report on the therapeutic efficacy and toxicity of a combination of FLU, idarubicin and cycloph...